Titre : Inositol phosphates

Inositol phosphates : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inositol phosphates : Questions médicales les plus fréquentes", "headline": "Inositol phosphates : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inositol phosphates : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-23", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inositol phosphates" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Oses phosphates", "url": "https://questionsmedicales.fr/mesh/D013403", "about": { "@type": "MedicalCondition", "name": "Oses phosphates", "code": { "@type": "MedicalCode", "code": "D013403", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D09.894" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inositol 1,4,5-trisphosphate", "alternateName": "Inositol 1,4,5-Trisphosphate", "url": "https://questionsmedicales.fr/mesh/D015544", "about": { "@type": "MedicalCondition", "name": "Inositol 1,4,5-trisphosphate", "code": { "@type": "MedicalCode", "code": "D015544", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D09.894.480.350" } } }, { "@type": "MedicalWebPage", "name": "Acide phytique", "alternateName": "Phytic Acid", "url": "https://questionsmedicales.fr/mesh/D010833", "about": { "@type": "MedicalCondition", "name": "Acide phytique", "code": { "@type": "MedicalCode", "code": "D010833", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D09.894.480.700" } } } ], "about": { "@type": "MedicalCondition", "name": "Inositol phosphates", "alternateName": "Inositol Phosphates", "code": { "@type": "MedicalCode", "code": "D007295", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Adolfo Saiardi", "url": "https://questionsmedicales.fr/author/Adolfo%20Saiardi", "affiliation": { "@type": "Organization", "name": "Medical Research Council Laboratory for Molecular Cell Biology, University College London, WC1E6BT, London, UK. Electronic address: a.saiardi@ucl.ac.uk." } }, { "@type": "Person", "name": "Henning J Jessen", "url": "https://questionsmedicales.fr/author/Henning%20J%20Jessen", "affiliation": { "@type": "Organization", "name": "Institute of Organic Chemistry & CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany." } }, { "@type": "Person", "name": "Gabriel Schaaf", "url": "https://questionsmedicales.fr/author/Gabriel%20Schaaf", "affiliation": { "@type": "Organization", "name": "Department of Plant Nutrition, Institute of Crop Science and Resource Conservation, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany. gabriel.schaaf@uni-bonn.de." } }, { "@type": "Person", "name": "Debabrata Laha", "url": "https://questionsmedicales.fr/author/Debabrata%20Laha", "affiliation": { "@type": "Organization", "name": "Medical Research Council Laboratory for Molecular Cell Biology, University College London, WC1E6BT, London, UK." } }, { "@type": "Person", "name": "Stephen B Shears", "url": "https://questionsmedicales.fr/author/Stephen%20B%20Shears", "affiliation": { "@type": "Organization", "name": "Inositol Signaling Section, NIEHS, 111, Alexander Drive, Research Triangle Park, Durham, NC 27709, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?", "datePublished": "2023-02-03", "url": "https://questionsmedicales.fr/article/36718727", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/14737140.2023.2171991" } }, { "@type": "ScholarlyArticle", "name": "The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.", "datePublished": "2023-05-02", "url": "https://questionsmedicales.fr/article/37534902", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4103/aja20239" } }, { "@type": "ScholarlyArticle", "name": "Simultaneous thulium laser resection of the prostate and transperineal prostate biopsy in clinically diagnosed metastatic prostate cancer with bladder outlet obstruction.", "datePublished": "2023-08-18", "url": "https://questionsmedicales.fr/article/37596454", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10103-023-03848-5" } }, { "@type": "ScholarlyArticle", "name": "Staging Prostate Cancer with", "datePublished": "2023-04-28", "url": "https://questionsmedicales.fr/article/37116912", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2967/jnumed.122.265371" } }, { "@type": "ScholarlyArticle", "name": "Prostate MRI Qualification:", "datePublished": "2022-05-11", "url": "https://questionsmedicales.fr/article/35544372", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2214/AJR.22.27615" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Glucides", "item": "https://questionsmedicales.fr/mesh/D002241" }, { "@type": "ListItem", "position": 3, "name": "Oses phosphates", "item": "https://questionsmedicales.fr/mesh/D013403" }, { "@type": "ListItem", "position": 4, "name": "Inositol phosphates", "item": "https://questionsmedicales.fr/mesh/D007295" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inositol phosphates - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inositol phosphates", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inositol phosphates", "description": "Comment diagnostiquer un déséquilibre en inositol phosphates ?\nQuels tests sont utilisés pour évaluer les inositol phosphates ?\nLes inositol phosphates sont-ils mesurables dans les tissus ?\nY a-t-il des marqueurs spécifiques pour les inositol phosphates ?\nLes tests génétiques sont-ils utiles pour les inositol phosphates ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Prostatic+Neoplasms&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inositol phosphates", "description": "Quels symptômes sont associés à un déséquilibre en inositol phosphates ?\nLes inositol phosphates affectent-ils la santé mentale ?\nY a-t-il des signes physiques d'un déséquilibre ?\nLes inositol phosphates influencent-ils le métabolisme ?\nPeut-on observer des symptômes neurologiques ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Prostatic+Neoplasms&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inositol phosphates", "description": "Comment prévenir les déséquilibres en inositol phosphates ?\nLes suppléments sont-ils nécessaires pour la prévention ?\nY a-t-il des habitudes de vie à adopter ?\nLes consultations médicales sont-elles importantes ?\nLes facteurs environnementaux influencent-ils les niveaux ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Prostatic+Neoplasms&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inositol phosphates", "description": "Quels traitements existent pour les déséquilibres en inositol phosphates ?\nLes médicaments peuvent-ils aider avec les inositol phosphates ?\nY a-t-il des thérapies alternatives pour les inositol phosphates ?\nComment les changements alimentaires aident-ils ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Prostatic+Neoplasms&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inositol phosphates", "description": "Quelles complications peuvent survenir avec des déséquilibres ?\nLes inositol phosphates sont-ils liés à des maladies chroniques ?\nY a-t-il des risques pour la santé reproductive ?\nLes complications neurologiques sont-elles fréquentes ?\nLes complications psychologiques sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Prostatic+Neoplasms&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inositol phosphates", "description": "Quels sont les facteurs de risque pour les déséquilibres ?\nL'âge influence-t-il les niveaux d'inositol phosphates ?\nLes maladies métaboliques sont-elles un facteur de risque ?\nLe mode de vie sédentaire est-il un risque ?\nLes facteurs environnementaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Prostatic+Neoplasms&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un déséquilibre en inositol phosphates ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins peuvent mesurer les niveaux d'inositol phosphates dans le corps." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les inositol phosphates ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests biochimiques et les analyses de métabolites urinaires sont courants." } }, { "@type": "Question", "name": "Les inositol phosphates sont-ils mesurables dans les tissus ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biopsies peuvent être effectuées pour évaluer les niveaux dans les tissus." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour les inositol phosphates ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme l'IP3 peuvent indiquer des déséquilibres dans la signalisation cellulaire." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour les inositol phosphates ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent aider à identifier des troubles métaboliques liés aux inositol phosphates." } }, { "@type": "Question", "name": "Quels symptômes sont associés à un déséquilibre en inositol phosphates ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, troubles de l'humeur et problèmes métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les inositol phosphates affectent-ils la santé mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres peuvent être liés à des troubles de l'humeur comme la dépression." } }, { "@type": "Question", "name": "Y a-t-il des signes physiques d'un déséquilibre ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des troubles de la peau ou des problèmes digestifs peuvent apparaître." } }, { "@type": "Question", "name": "Les inositol phosphates influencent-ils le métabolisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils jouent un rôle dans la régulation du métabolisme lipidique et glucidique." } }, { "@type": "Question", "name": "Peut-on observer des symptômes neurologiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles cognitifs et de la mémoire peuvent être liés à des déséquilibres." } }, { "@type": "Question", "name": "Comment prévenir les déséquilibres en inositol phosphates ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain sont essentiels pour la prévention." } }, { "@type": "Question", "name": "Les suppléments sont-ils nécessaires pour la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments peuvent être bénéfiques, surtout en cas de carence alimentaire." } }, { "@type": "Question", "name": "Y a-t-il des habitudes de vie à adopter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "L'exercice régulier et la gestion du stress peuvent aider à maintenir l'équilibre." } }, { "@type": "Question", "name": "Les consultations médicales sont-elles importantes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des bilans réguliers peuvent aider à détecter des déséquilibres précocement." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils les niveaux ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines peut affecter le métabolisme des inositol phosphates." } }, { "@type": "Question", "name": "Quels traitements existent pour les déséquilibres en inositol phosphates ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments d'inositol et des modifications alimentaires peuvent être recommandés." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider avec les inositol phosphates ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments psychotropes peuvent influencer les niveaux d'inositol phosphates." } }, { "@type": "Question", "name": "Y a-t-il des thérapies alternatives pour les inositol phosphates ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la phytothérapie peuvent être explorées, mais nécessitent des études." } }, { "@type": "Question", "name": "Comment les changements alimentaires aident-ils ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en fruits et légumes peut améliorer les niveaux d'inositol." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés selon les besoins individuels et les symptômes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des déséquilibres ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles métaboliques, neurologiques et psychologiques peuvent se développer." } }, { "@type": "Question", "name": "Les inositol phosphates sont-ils liés à des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres peuvent être associés à des maladies comme le diabète." } }, { "@type": "Question", "name": "Y a-t-il des risques pour la santé reproductive ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des déséquilibres peuvent affecter la fertilité et la santé reproductive." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles cognitifs peuvent survenir en cas de déséquilibre prolongé." } }, { "@type": "Question", "name": "Les complications psychologiques sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines peuvent être réversibles avec un traitement approprié et un suivi." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les déséquilibres ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation pauvre, le stress et des antécédents familiaux peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux d'inositol phosphates ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux peuvent diminuer avec l'âge, augmentant le risque de déséquilibre." } }, { "@type": "Question", "name": "Les maladies métaboliques sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conditions comme le diabète peuvent affecter le métabolisme des inositol phosphates." } }, { "@type": "Question", "name": "Le mode de vie sédentaire est-il un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie inactif peut contribuer à des déséquilibres en inositol phosphates." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines peut perturber le métabolisme des inositol phosphates." } } ] } ] }

Sources (10000 au total)

Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?

The paradigm of focal therapy's role in metastatic patients is being challenged by evolving attitudes and emerging data. At the current time, specifically regarding prostate cancer, does the evidence ... We searched the literature via PubMed, MEDLINE, and Embase for studies from 2014 to the present addressing focal therapy with non-palliative intent in metastatic prostate cancer patients, emphasizing ... Current evidence is strongest, and in our opinion practice-changing, for prostate-directed RT in de novo metastatic patients with low metastatic burden. Metastasis-directed therapy with SBRT is consis...

Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.

There is a clinical need to identify patients with an elevated PSA who would benefit from prostate biopsy due to the presence of clinically significant prostate cancer (CSCaP). We have previously repo... To further develop and adapt the MiCheck® Prostate test so it can be performed using a standard clinical chemistry analyzer and characterize its performance using the MiCheck-01 clinical trial sample ... About 358 patient samples from the MiCheck-01 US clinical trial were used for the development of the MiCheck® Prostate test. These consisted of 46 controls, 137 non-CaP, 62 non-CSCaP, and 113 CSCaP.... Serum analyte concentrations for cellular growth factors were determined using custom-made Luminex-based R&D Systems multi-analyte kits. Analytes that can also be measured using standard chemistry ana... Logistic regression modeling with Monte Carlo cross-validation was used to identify Human Epidydimal Protein 4 (HE4) as an analyte able to significantly improve the algorithm specificity at 95% sensit... The MiCheck® logistic regression model was developed and consisted of PSA, %free PSA, DRE, and HE4. The model differentiated clinically significant cancer from no cancer or not-clinically significant ... The MiCheck® Prostate test identifies clinically significant prostate cancer with high sensitivity and negative predictive value (NPV). It can be performed in a clinical laboratory using a Roche Cobas...

New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.

Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinica... Proclarix and PHI were measured using samples of 344 men from two different centers. All patients underwent prostate biopsy, and among those, 188 men with PCa on biopsy had an additional radical prost... The cohort median age and PSA were 65 (interquartile range [IQR]: 60-71) and 5.6 (IQR: 4.3-7.2) ng/ml, respectively. CsPCa was diagnosed in 161 (47%) men based on the RP specimen. ROC analysis showed ... Results of this study show that both Proclarix and PHI accurately detect the presence of csPCa. The model combining Proclarix and PHI revealed the synergistic effect and improved the diagnostic perfor...

Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates.

Transperineal (TP) multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) has been shown to detect more clinically significant (cs) prostate cancer (PCa) than standard template biops... We identified all men who with suspicious lesions on mpMRI and underwent TP TBx (3-core) and concomitant SBx (20-core) in our single hospital from September 2019 to February 2021. Clinical, MRI and bi... Three hundred and one (n = 301) men were included. The median prostate volume by MRI was 45 ml. The patients were divided by prostate volume into three groups: ≤30ml group (19.9%), >30 to ≤45 ml group... Our data suggest that performing TBx with limited additional cores may potentially achieve the same csPCa detection rate as the combined SBx and TBx in smaller prostates....

Are elevated mitochondrial DNA fragments in prostatic inflammation a potential biomarker for prostate cancer?

We sought to determine whether two soluble forms with different size of mtDNA are linked to prostatic inflammation, and whether they discriminate prostate cancer (PCa) from inflammatory prostatic cond... Histopathologically diagnosed prostatitis, PCa and benign prostatic hyperplasia patients (n = 93) were enrolled in this study and they were categorized as with and without prostate inflammation. Quant... The urine mtDNA-79 and mtDNA-230 were significantly increased in patients with prostate inflammation compared with those in without inflammation. Here, 79-bp fragment of apoptotic origin was significa... Our results demonstrate that shorter cf-mtDNA fragment size in particular, increase in the presence of prostate inflammation in post-prostatic massage urine but both fragments could never improve seru...